SUPN: חוב כולל להון Supernus

The business stability of Supernus Pharmaceuticals (SUPN) is ensured by the protection of intellectual property rights in the US and the absence of geopolitical threats. This chart reflects a price trend demonstrating a total debt-to-equity ratio of 0.03. The company focuses on long-term CNS research, creating an ethical environment for scientists. Asset value growth is driven by sales of ADHD medication and the development of an innovative pump.

This ratio compares total liabilities to net assets, determining the business's dependence on external financing and the risks of insolvency amid rising interest rates. For Supernus Pharmaceuticals (SUPN), whose revenues are stabilized by long-term CNS therapy, this balance is critical for maintaining growth rates, which is clearly reflected in the leverage level relative to equity on the GURU.Markets platform.